Heart Success! Bilateral mastectomies in breast cancer, the PARADIGM-HF Heart Failure Trial

Subscribe on iTunes

This week: Changes in incidence and mortality associated with bilateral mastectomy for breast cancer and Neprilysin-inhibition for heart failure

Nathan and Amol want you to:

1. Recognize that bilateral mastectomies for breast cancer are increasing in incidence, perhaps because of increased use of MRI, and they are not associated with a reduction in mortality.

2. Understand that the PARADIGM-HF trial demonstrated that neprilysin-inhibition in heart failure reduced mortality compared to ace-inhibition, which may change treatment of this important disease.

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

AW Kurian et al. Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011. JAMA 2014;312(9):902-914. (PubMed).

JJ McMurray et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014; 371:993-1004. (PubMed). 

Good stuff


Why it makes sense to bike without a helmet, Howie Chong, February 24, 2014.


President’s Valedictory Address: Dr. Louis Hugo Francescutti, Canadian Medical Association (Video).

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more